[go: up one dir, main page]

AR109816A2 - Forma de dosificación farmacéutica para administración oral de un inhibidor de la familia bcl-2 - Google Patents

Forma de dosificación farmacéutica para administración oral de un inhibidor de la familia bcl-2

Info

Publication number
AR109816A2
AR109816A2 ARP170102786A ARP170102786A AR109816A2 AR 109816 A2 AR109816 A2 AR 109816A2 AR P170102786 A ARP170102786 A AR P170102786A AR P170102786 A ARP170102786 A AR P170102786A AR 109816 A2 AR109816 A2 AR 109816A2
Authority
AR
Argentina
Prior art keywords
dosage form
pharmaceutical dosage
bcl
oral administration
family inhibitor
Prior art date
Application number
ARP170102786A
Other languages
English (en)
Inventor
Martin Knobloch
Drazen Kostelac
Bernd Liepold
Norbert Steiger
Claudia Packhaeuser
Original Assignee
Abbott Gmbh & Co Kg
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43063251&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR109816(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Abbott Gmbh & Co Kg filed Critical Abbott Gmbh & Co Kg
Publication of AR109816A2 publication Critical patent/AR109816A2/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/63—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
    • A61K31/635—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide having a heterocyclic ring, e.g. sulfadiazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4833—Encapsulating processes; Filling of capsules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Forma de dosificación farmacéutica que comprende un producto de dispersión sólida que comprende N-(4-(4-((2-(4-clorofenil)-5,5-dimetil-1-ciclohex-1-en-1-il)metil)piperazin-1-il)benzoil)-4-(((1R)-3-(morfolin-4-il)-1-((fenilsulfanil)metil)propil)amino)-3-((trifluorometil)sulfonil)bencenosulfonamida o una sal, hidrato o solvato de la misma, al menos un polímero farmacéuticamente aceptable, y al menos un solubilizante farmacéuticamente aceptable. Procesos para preparar la forma de dosificación farmacéutica y para usar la forma de dosificación para tratar trastornos proliferativos.
ARP170102786A 2009-06-08 2017-10-05 Forma de dosificación farmacéutica para administración oral de un inhibidor de la familia bcl-2 AR109816A2 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US18513009P 2009-06-08 2009-06-08

Publications (1)

Publication Number Publication Date
AR109816A2 true AR109816A2 (es) 2019-01-23

Family

ID=43063251

Family Applications (2)

Application Number Title Priority Date Filing Date
ARP100102011A AR077021A1 (es) 2009-06-08 2010-06-08 Formas de dosificacion farmaceutica para administracion oral de un inhibidor de la familia bcl 2
ARP170102786A AR109816A2 (es) 2009-06-08 2017-10-05 Forma de dosificación farmacéutica para administración oral de un inhibidor de la familia bcl-2

Family Applications Before (1)

Application Number Title Priority Date Filing Date
ARP100102011A AR077021A1 (es) 2009-06-08 2010-06-08 Formas de dosificacion farmaceutica para administracion oral de un inhibidor de la familia bcl 2

Country Status (37)

Country Link
US (6) US9642796B2 (es)
EP (3) EP2982366B1 (es)
JP (2) JP5872459B2 (es)
KR (2) KR101751216B1 (es)
CN (2) CN102802606A (es)
AR (2) AR077021A1 (es)
AU (1) AU2010258367B2 (es)
BR (2) BR122018076978B1 (es)
CA (1) CA2763441C (es)
CL (1) CL2011003054A1 (es)
CO (1) CO6480964A2 (es)
CR (1) CR20170037A (es)
CY (1) CY1119663T1 (es)
DK (2) DK2982366T3 (es)
DO (2) DOP2011000375A (es)
EC (1) ECSP12011580A (es)
ES (2) ES2651307T3 (es)
HR (2) HRP20151342T1 (es)
HU (2) HUE025638T2 (es)
IL (2) IL216494A (es)
LT (1) LT2982366T (es)
MX (1) MX2011013164A (es)
MY (1) MY159824A (es)
NO (1) NO2982366T3 (es)
NZ (1) NZ597241A (es)
PE (2) PE20121084A1 (es)
PL (2) PL2982366T3 (es)
PT (2) PT2982366T (es)
RU (2) RU2711359C2 (es)
SG (1) SG176264A1 (es)
SI (2) SI2982366T1 (es)
SM (1) SMT201500317B (es)
TW (2) TWI471321B (es)
UA (1) UA104471C2 (es)
UY (1) UY32695A (es)
WO (1) WO2010143074A2 (es)
ZA (1) ZA201108853B (es)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI471321B (zh) 2009-06-08 2015-02-01 亞培公司 Ｂｃｌ－２族群抑制劑之口服醫藥劑型
AU2011264993B2 (en) 2010-06-09 2014-02-06 Abbvie Bahamas Ltd. Solid dispersions containing kinase inhibitors
TWI535712B (zh) 2010-08-06 2016-06-01 阿斯特捷利康公司 化合物
EP2632436B1 (en) * 2010-10-29 2018-08-29 Abbvie Inc. Solid dispersions containing an apoptosis-inducing agent
UA113500C2 (xx) 2010-10-29 2017-02-10 Одержані екструзією розплаву тверді дисперсії, що містять індукуючий апоптоз засіб
JP6141188B2 (ja) 2010-11-23 2017-06-07 アッヴィ・インコーポレイテッド アポトーシス誘導剤の塩および結晶の形態
NZ708508A (en) 2010-11-23 2016-06-24 Abbvie Bahamas Ltd Methods of treatment using selective bcl-2 inhibitors
KR102191562B1 (ko) * 2012-11-07 2020-12-15 에스케이바이오팜 주식회사 난용성 약물의 고체분산체 및 이의 제조방법
US20160022708A1 (en) * 2013-03-14 2016-01-28 St. Jude Children's Research Hospital Methods and compositions for the treatment of glutamine-addicted cancers
US20140275082A1 (en) 2013-03-14 2014-09-18 Abbvie Inc. Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases
US10111897B2 (en) 2013-10-03 2018-10-30 Duke University Compositions and methods for treating cancer with JAK2 activity
EP3129407A2 (en) * 2014-03-12 2017-02-15 Novartis Ag Specific sites for modifying antibodies to make immunoconjugates
JP6831704B2 (ja) * 2014-06-18 2021-02-17 エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト 非イオン界面活性剤を含む新規の薬学的組成物
CN105616419A (zh) * 2014-11-07 2016-06-01 江苏豪森药业集团有限公司 含有细胞周期蛋白抑制剂固体分散体的药物组合物及其制备方法
US10246461B2 (en) 2016-02-29 2019-04-02 Genentech, Inc. Dosage form compositions comprising an inhibitor of bruton's tyrosine kinase
JOP20190191A1 (ar) 2017-02-22 2019-08-08 Astrazeneca Ab وحدات شجرية علاجية
US11872237B2 (en) 2018-12-28 2024-01-16 Ascentage Pharma (Suzhou) Co., Ltd. Pharmaceutical composition and preparation method thereof
JP2022553820A (ja) 2019-11-05 2022-12-26 アッヴィ・インコーポレイテッド 骨髄線維症及びｍｐｎ関連障害をナビトクラクスで処置する際に使用するための投与レジメン
WO2021173523A1 (en) * 2020-02-24 2021-09-02 Newave Pharmaceutical Inc. Hot melt extruded solid dispersions containing a bcl2 inhibitor
CN114533677A (zh) * 2020-11-25 2022-05-27 苏州亚盛药业有限公司 固体分散体、制剂、其制备方法及其应用
US20240091183A1 (en) * 2021-01-08 2024-03-21 Syros Pharmaceuticals, Inc. Treatment regimens with fixed doses of tamibarotene
CN113520995B (zh) * 2021-08-16 2023-03-10 海南鑫开源医药科技有限公司 一种离子敏感型眼用原位凝胶、其制备方法及应用
TW202345857A (zh) * 2022-03-08 2023-12-01 美商昂科斯克塞爾醫療有限責任公司 他波司他之穩定調配物

Family Cites Families (64)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5665379A (en) 1990-09-28 1997-09-09 Pharmacia & Upjohn Aktiebolag Lipid particle forming matrix, preparation and use thereof
GB9309509D0 (en) * 1993-05-07 1993-06-23 Merck Patent Gmbh Thrombin inhibitors
US5536729A (en) 1993-09-30 1996-07-16 American Home Products Corporation Rapamycin formulations for oral administration
IL111004A (en) 1993-09-30 1998-06-15 American Home Prod Oral formulations of rapamycin
AU692506B2 (en) 1993-11-17 1998-06-11 Ibah, Inc. Transparent liquid for encapsulated drug delivery
US5759548A (en) 1993-11-30 1998-06-02 Lxr Biotechnology Inc. Compositions which inhibit apoptosis, methods of purifying the compositions and uses thereof
GB9405304D0 (en) 1994-03-16 1994-04-27 Scherer Ltd R P Delivery systems for hydrophobic drugs
US5538737A (en) 1994-11-30 1996-07-23 Applied Analytical Industries, Inc. Oral compositions of H2 -antagonists
BE1009856A5 (fr) 1995-07-14 1997-10-07 Sandoz Sa Composition pharmaceutique sous la forme d'une dispersion solide comprenant un macrolide et un vehicule.
US6964946B1 (en) 1995-10-26 2005-11-15 Baker Norton Pharmaceuticals, Inc. Oral pharmaceutical compositions containing taxanes and methods of treatment employing the same
US5891469A (en) 1997-04-02 1999-04-06 Pharmos Corporation Solid Coprecipitates for enhanced bioavailability of lipophilic substances
BE1011899A6 (fr) 1998-04-30 2000-02-01 Ucb Sa Compositions pharmaceutiques gelifiables utilisables.
US6294192B1 (en) 1999-02-26 2001-09-25 Lipocine, Inc. Triglyceride-free compositions and methods for improved delivery of hydrophobic therapeutic agents
US6267985B1 (en) 1999-06-30 2001-07-31 Lipocine Inc. Clear oil-containing pharmaceutical compositions
DE19913692A1 (de) 1999-03-25 2000-09-28 Basf Ag Mechanisch stabile pharmazeutische Darreichungsformen, enthaltend flüssige oder halbfeste oberflächenaktive Substanzen
DE19929361A1 (de) 1999-06-25 2001-01-04 Basf Ag Mechanisch stabile pharmazeutische Darreichungsformen, enthaltend flüssige oder halbfeste oberflächenaktive Substanzen
US6982281B1 (en) * 2000-11-17 2006-01-03 Lipocine Inc Pharmaceutical compositions and dosage forms for administration of hydrophobic drugs
US6309663B1 (en) 1999-08-17 2001-10-30 Lipocine Inc. Triglyceride-free compositions and methods for enhanced absorption of hydrophilic therapeutic agents
US20060183776A9 (en) 2000-03-03 2006-08-17 Eisai Co., Ltd. Liquid dosage formulations of donepezil
AR031130A1 (es) 2000-09-20 2003-09-10 Abbott Lab N-acilsulfonamidas promotoras de la apoptosis
US20020055631A1 (en) 2000-09-20 2002-05-09 Augeri David J. N-acylsulfonamide apoptosis promoters
WO2002060896A1 (en) 2001-01-31 2002-08-08 Pfizer Products Inc. Ether derivatives useful as inhibitors of pde4 isozymes
GB0123400D0 (en) * 2001-09-28 2001-11-21 Novartis Ag Organic compounds
DK1471887T3 (da) 2002-02-04 2010-06-07 Elan Pharma Int Ltd Nanopartikelkompositioner der har lysozym som overfladestabiliseringsmiddel
KR101002374B1 (ko) * 2002-02-26 2010-12-17 아스트라제네카 아베 수용성 셀룰로스 유도체를 포함하는 이레사의 약학 조제물
JO2479B1 (en) 2002-04-29 2009-01-20 ميرك شارب اند دوم ليمتد Rates for the activity of the chemokine receptor of tetrahydrobranyl cycloneptil tetrahydrobredo predine
US20060177430A1 (en) 2002-12-20 2006-08-10 Chakshu Research Inc Treatment of ocular disorders with ophthalmic formulations containing methylsulfonylmethane as a transport enhancer
US8025899B2 (en) * 2003-08-28 2011-09-27 Abbott Laboratories Solid pharmaceutical dosage form
US8377952B2 (en) 2003-08-28 2013-02-19 Abbott Laboratories Solid pharmaceutical dosage formulation
US20050048112A1 (en) 2003-08-28 2005-03-03 Jorg Breitenbach Solid pharmaceutical dosage form
WO2005049593A2 (en) 2003-11-13 2005-06-02 Abbott Laboratories N-acylsulfonamide apoptosis promoters
US7973161B2 (en) 2003-11-13 2011-07-05 Abbott Laboratories Apoptosis promoters
US7790190B2 (en) 2004-03-20 2010-09-07 Yasoo Health, Inc. Aqueous emulsions of lipophile solubilized with vitamin E TPGS and linoleic acid
US7318503B2 (en) 2004-04-26 2008-01-15 Akebono Corporation (North America) Pad retaining clips
FR2875409B1 (fr) 2004-09-17 2010-05-07 Sanofi Aventis Composition pharmaceutique comprenant une dispersion solide a matrice polymere comprenant une phase continue de polydextrose et une phase continue d'un polymere autre que du polydextrose
DK1888550T3 (da) * 2005-05-12 2014-09-29 Abbvie Bahamas Ltd Apoptosepromotorer
CN1706371B (zh) 2005-05-27 2010-11-10 沈阳药科大学 一种高效的马蔺子素制剂及其制备方法
EP1933809B1 (en) 2005-10-11 2012-02-08 Yissum Research Development Company Of The Hebrew University Of Jerusalem Compositions for nasal delivery
JP2009513642A (ja) 2005-10-25 2009-04-02 アボット・ラボラトリーズ 低水溶解度の薬剤を含む製剤およびそれの使用方法
US7151188B1 (en) 2005-11-16 2006-12-19 General Electric Company Process for the production of mercaptoalkylalkoxysilanes
WO2007133796A2 (en) 2006-05-15 2007-11-22 Encysive Pharmaceuticals, Inc. Methods and compositions for treatment of sleep apnea comprising administration of an endothelin antagonist
MX2009000132A (es) * 2006-06-30 2009-01-26 Schering Corp Metodo para el uso de piperidinas sustituidas que incrementan la actividad de p53.
EP1880715A1 (en) * 2006-07-19 2008-01-23 Abbott GmbH & Co. KG Pharmaceutically acceptable solubilizing composition and pharmaceutical dosage form containing same
MX2009002422A (es) 2006-09-05 2009-03-20 Abbott Lab Inhibidores bcl para tratar exceso de plaquetas.
WO2008064116A2 (en) 2006-11-16 2008-05-29 Abbott Laboratories Method of preventing or treating organ, hematopoietic stem cell or bone marrow transplant rejection
RU2351352C2 (ru) 2007-04-09 2009-04-10 Закрытое акционерное общество "Санкт-Петербургский институт фармации" Твердая нанокомпозиция для доставки биологически активных веществ
US8536157B2 (en) 2007-04-13 2013-09-17 The University Of Melbourne Non-steroidal compounds
BRPI0817664A2 (pt) 2007-10-12 2015-03-24 Massachusetts Inst Technology Nanopartículas, método para preparar nanopartículas e método para tratar terapeuticamente ou profilaticamente um indivíduo
CN101939008A (zh) * 2007-12-06 2011-01-05 雅培制药有限公司 用于治疗癌症的abt-263经口组合物
CN101220008B (zh) * 2008-01-21 2011-04-27 中国科学院广州生物医药与健康研究院 化合物abt-263的合成方法
US8168784B2 (en) 2008-06-20 2012-05-01 Abbott Laboratories Processes to make apoptosis promoters
US8728516B2 (en) 2009-04-30 2014-05-20 Abbvie Inc. Stabilized lipid formulation of apoptosis promoter
US20100280031A1 (en) 2009-04-30 2010-11-04 Paul David Lipid formulation of apoptosis promoter
US20100278921A1 (en) 2009-04-30 2010-11-04 Fischer Cristina M Solid oral formulation of abt-263
US8362013B2 (en) 2009-04-30 2013-01-29 Abbvie Inc. Salt of ABT-263 and solid-state forms thereof
US20100297194A1 (en) 2009-04-30 2010-11-25 Nathaniel Catron Formulation for oral administration of apoptosis promoter
US8546399B2 (en) 2009-05-26 2013-10-01 Abbvie Inc. Apoptosis inducing agents for the treatment of cancer and immune and autoimmune diseases
TWI532484B (zh) 2009-06-08 2016-05-11 艾伯維有限公司 包含凋亡促進劑之固態分散劑
TWI471321B (zh) 2009-06-08 2015-02-01 亞培公司 Ｂｃｌ－２族群抑制劑之口服醫藥劑型
EP2442789A1 (en) 2009-06-18 2012-04-25 Abbott Laboratories Stable nanoparticulate drug suspension
MX2012003408A (es) 2009-09-20 2012-08-03 Abbott Lab Formas cristalinas de abt-263 y solvatos para uso para tratar enfermedades relacionadas con la proteina bcl-2.
CA2780177A1 (en) 2009-12-22 2011-06-30 Abbott Laboratories Abt-263 capsule
CN101798292A (zh) 2010-03-29 2010-08-11 无锡好芳德药业有限公司 ABT-263衍生的新型Bcl-2蛋白抑制剂的制备
AU2012318242A1 (en) 2011-11-11 2013-05-30 Sio2 Medical Products, Inc. Passivation, pH protective or lubricity coating for pharmaceutical package, coating process and apparatus

Also Published As

Publication number Publication date
MY159824A (en) 2017-02-15
PT2440177E (pt) 2015-12-01
CA2763441A1 (en) 2010-12-16
IL238477A0 (en) 2015-06-30
EP3272334A1 (en) 2018-01-24
ZA201108853B (en) 2012-08-29
DOP2017000057A (es) 2017-04-16
RU2015141869A (ru) 2018-12-29
RU2711359C2 (ru) 2020-01-16
JP6129999B2 (ja) 2017-05-17
DK2982366T3 (en) 2018-01-02
AU2010258367B2 (en) 2014-05-01
US20100310648A1 (en) 2010-12-09
PE20160043A1 (es) 2016-02-11
KR20170073714A (ko) 2017-06-28
US20170189426A1 (en) 2017-07-06
PL2982366T3 (pl) 2018-06-29
UA104471C2 (uk) 2014-02-10
KR101791404B1 (ko) 2017-10-30
TW201103925A (en) 2011-02-01
IL216494A (en) 2016-03-31
HK1220902A1 (en) 2017-05-19
JP2012529490A (ja) 2012-11-22
CA2763441C (en) 2018-01-02
EP2440177A2 (en) 2012-04-18
RU2011154143A (ru) 2013-07-20
ES2551860T3 (es) 2015-11-24
CY1119663T1 (el) 2018-04-04
EP2982366B1 (en) 2017-09-13
LT2982366T (lt) 2017-11-27
SI2440177T1 (sl) 2016-01-29
CL2011003054A1 (es) 2012-07-20
HUE025638T2 (en) 2016-04-28
CN106074391A (zh) 2016-11-09
IL216494A0 (en) 2012-01-31
HRP20171902T1 (hr) 2018-01-26
ECSP12011580A (es) 2012-02-29
MX2011013164A (es) 2012-04-20
RU2015141869A3 (es) 2019-04-19
SMT201500317B (it) 2016-02-25
EP2440177B1 (en) 2015-09-16
EP3272334B1 (en) 2019-03-06
US20210093649A1 (en) 2021-04-01
AU2010258367A1 (en) 2012-01-19
RU2568599C2 (ru) 2015-11-20
BRPI1012831A2 (pt) 2018-03-06
JP2016121159A (ja) 2016-07-07
IL238477A (en) 2017-01-31
NO2982366T3 (es) 2018-02-10
HK1169613A1 (en) 2013-02-01
TW201529572A (zh) 2015-08-01
HRP20151342T1 (hr) 2016-01-01
SI2982366T1 (en) 2018-01-31
TWI540132B (zh) 2016-07-01
US20190269704A1 (en) 2019-09-05
PL2440177T3 (pl) 2016-03-31
BRPI1012831B1 (pt) 2021-05-18
WO2010143074A3 (en) 2011-02-17
JP5872459B2 (ja) 2016-03-01
DOP2011000375A (es) 2011-12-31
US20220110951A1 (en) 2022-04-14
WO2010143074A2 (en) 2010-12-16
KR20120027049A (ko) 2012-03-20
PE20121084A1 (es) 2012-09-13
CO6480964A2 (es) 2012-07-16
NZ597241A (en) 2014-01-31
PT2982366T (pt) 2017-12-21
ES2651307T3 (es) 2018-01-25
UY32695A (es) 2010-12-31
CR20170037A (es) 2017-04-17
CN102802606A (zh) 2012-11-28
EP2982366A1 (en) 2016-02-10
BR122018076978B1 (pt) 2021-08-31
AR077021A1 (es) 2011-07-27
TWI471321B (zh) 2015-02-01
KR101751216B1 (ko) 2017-06-28
HUE035727T2 (en) 2018-05-28
SG176264A1 (en) 2012-01-30
US9642796B2 (en) 2017-05-09
DK2440177T3 (en) 2015-12-21
US20240197757A1 (en) 2024-06-20

Similar Documents

Publication Publication Date Title
AR109816A2 (es) Forma de dosificación farmacéutica para administración oral de un inhibidor de la familia bcl-2
NZ585085A (en) Method of treating arthritis using arylsulfonamide compounds
MX2010006260A (es) Composiciones orales de abt-263 para tratar cancer.
NZ598461A (en) Abt-263 crystalline forms and solvates for use in treating bcl-2 protein related diseases
EP4563150A3 (en) New crystalline forms of n-(3-(2-(2-hydroxyethoxy)-6-morpholinopyridin-4-yl)-4-methvlphenyl)-2(trifluoromethyl) isonicotinamide as raf inhibitors for the treatment of cancer
CY1114242T1 (el) Μια διεργασια για την παρασκευη του υποκινητη αποπτωσης αβτ-263
CL2012001133A1 (es) Composicion farmaceutica oral que comprende ponatinib 3-(imidazo[1,2-b]piridazin-3-iletinil)-4-metil-n-(4-((4-metilpiperazin-1-il)-metil)-3-(trifluorometil)fenil)benzamida y al menos un excipiente farmaceuticamente aceptable; y su uso para el tratamiento de neoplasma, cancer o un trastorno hiperproliferativo.
MX2021004110A (es) Composiciones farmaceuticas que comprenden n-(3,5- dimetoxifenil)-n'-(1-metiletil)-n-[3-(1-metil-1h- pirazol-4-il)quinoxalin-6-il]etano-1,2-diamina.
JP2013531028A5 (es)
MX2013005851A (es) Sales y formas cristalinas de un agente inductor de apoptosis.
AR079208A2 (es) Inhibidores de la actividad de proteina tirosina quinasa, composicion y uso de dichos inhibidores para la preparacion de un medicamento para tratar una enfermedad, trastorno o condicion oftalmica
CO2020000168A2 (es) Preparación sólida de cariprazina para administración oral
JP2009541443A5 (es)
ECSP22098275A (es) Formas de dosificación oral sólidas de combinación de antagonistas de la hormona liberadora de gonadotropina
MX2025005474A (es) Farmaco farmaceutico que contiene derivado de heterocicliden acetamida
AR109652A1 (es) Métodos para utilizar agonistas de fxr
CR20110663A (es) Forma de dosificaciën farmacuutica para administraciën oral de un inhibidor de la familia bcl 2
CY1117296T1 (el) Φαρμακευτικη μορφη δοσολογιας για απο του στοματος χορηγηση ενος αναστολεα της οικογενειας bcl-2
TH127003A (th) รูปฟอร์มขนาดใช้ในทางเภสัชกรรมสำหรับการดำเนินการให้ผ่านทางปากของสารยับยั้ง bcl-2 แฟมมิลี
MX2016017402A (es) Composicion farmaceutica para administracion oral.
EA032957B1 (ru) Комбинация обратных агонистов гистамин-3 рецептора с ингибиторами ацетилхолинэстеразы
AR099283A1 (es) Composiciones y métodos para el tratamiento de enfermedades virales con moduladores de la pde4
BR112018073951A2 (pt) forma cristalina inovadora de n-[5-(3,5-difluoro-benzil)-1h-indazol-3-il]-4-(4-metil-piperazin-1-il)-2-(tetra-hidro-piran-4-ilamino)-benzamida
CL2007003806A1 (es) Compuestos derivados de n-(2h-pirazol-3-il)-amida, inhibidores del fgfr; composicion farmaceutica que comprende a dichos compuestos; su proceso de preparacion; y su uso para el tratamiento del cancer.

Legal Events

Date Code Title Description
FB Suspension of granting procedure